ELMMB logo
Facebook logo Twitter logo
Menu
Drug Alerts and Withdrawals

Drug Alerts and Withdrawals

Within the UK, the Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health aim to enhance and safeguard the health of the public by ensuring that medicines and medical devices work and are acceptably safe. No product is risk-free. Underpinning their work lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.

  • The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe.
  • No product is risk-free. Underpinning the work of the MHRA lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.
  • The MHRA keep watch over medicines and devices, and take any necessary action to protect the public promptly if there is a problem.
  • The MHRA aim to make as much information as possible publicly available. The MHRA enable greater access to products, and the timely introduction of innovative treatments and technologies that benefit patients and the public.
  • The MHRA encourage everyone - the public and healthcare professionals as well as industry - to tell us about any problems with a medicine or medical device, so that we can investigate and take any necessary action. To find out more about the MHRA click here...

When the MHRA, or occasionally another regulatory body in another country, such as the FDA, release advice, it is sometime necessary to produce additional local guidance.  This aims to be both clear and concise advice to healthcare professionals on the local action required to implement or respond to alerts issued by the MHRA or other bodies.  These memorandums are available below for reference, once they have been circulated to the relevant professionals in primary and secondary care:

MHRA News Stories.

 26th May 2020              MHRA Press Release - MHRA supports use of remdesivir as the first medicines to treat COVID-19 in the UK
 6th May 2020                MHRA Press Release - NEW Yellow Card COVID-19 reporting site
12th February 2020      MHRA Press Release  - Integrated Yellow Card reporting now available in 93% of GP practices in the UK
19th November 2019   MHRA Press Release - Ranitidine Oral Solution & Tablets recall
                                                     
                                                 


MHRA Company-led Drug alerts

click here to access the most recent alerts

Items In This Category

 TitleCreatedDownload
application/pdfPicato 150mcg per g gel Class 2 medicines recall 270120.pdf (196KB)27/01/2020Download
 LEO Laboratories Ltd (T/A LEO Pharma) is recalling all unexpired stock of the above products from pharmacies and wholesalers as a precautionary measure due to concerns on the possible risk of skin... 
application/pdfRanitidine 150mg 300mg tablets Medley Pharma EL__19_A_41_Final.pdf (100KB)17/12/2019Download
 Medley Pharma Limited is recalling all unexpired stock of the above products from pharmacies and retail stores as a precautionary measure due to possible contamination with an impurity... 
application/pdfMetformin EMA Update_diabetes-medicines_en121219.pdf (126KB)12/12/2019Download
 EMA update on metformin diabetes medicines: EMA is aware that trace amounts of an impurity, N-nitrosodimethylamine (NDMA), have been found in a small number of metformin diabetes medicines outside... 
application/pdfRanitidine 150mg 300mg Class 3 meds recall Accord 051219_Final_2.pdf (99KB)05/12/2019Download
 ranitidine, accord, medicines, recall, drug,safety, dsu 
application/pdfDrug Safety Update July 19 Febuxostat.pdf (159KB)02/12/2019Download
 Increased risk of cardiovascular death and all-cause mortality in clinical trials in patients with a history of major cardiovascular disease 
application/pdfEmerade 150_300_and_500_microgram_solution_for_injection pfs Class_2_Medicines_Recall_Emerade_281119 (250KB)29/11/2019Download
 Pharmaswiss ńĆeska republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) is recalling all unexpired batches of the above product due an error in one component of the autoinjector believed to... 
application/pdfRanit oral 30mgml 150mg tabs Class 2 meds recall_EL__19_A_36_Final (1).pdf (123KB)20/11/2019Download
  
application/pdfFolic Acid 5mg tabs_accord_UK_ Cl3 meds recall_EL__19_A_35_Final.pdf (108KB)19/11/2019Download
 Accord-UK Ltd has informed us of an issue related to decommissioning of the above batch. Upon decommissioning at the pharmacy, there have been reports stating that when scanning the serialised 2D... 
application/pdfSayana Press Class 2 Medicines recall Sayana Press Oct 19.pdf (138KB)23/10/2019Download
 Pfizer Ltd has informed us of an issue related to the sealing process for some units of Sayana Press for subcutaneous (SC) injection potentially impacting the above listed batches. Sayana Press for... 
application/pdfRifadin_Rifampicin 150mg capsules CLASS 4 MEDICINES DEFECT INFORMATION October 2019.pdf (129KB)23/10/2019Download
 Sanofi has informed us that a change to the Patient Information Leaflet (PIL) for this product has not been implemented by the required timeline.  
application/pdfXonvea 10mg Class 4 Medicines Recall__October 2019.pdf (127KB)23/10/2019Download
 Alliance Pharmaceuticals Ltd has informed us that the Patient Information Leaflet (PIL) is missing the possible side effects from post-marketing experience and the associated class effects that are... 
application/pdfClass 2 medicines recall: Ranitidine Effervescent Tablets Drug alert_Oct 19.pdf (194KB)23/10/2019Download
 Teva UK Limited trading as ratiopharm GmbH is recalling all unexpired stock of Ranitidine Effervescent Tablets from pharmacies. 
Page: [1] [2] [3] [4] [5] [6]